BeiGene
BGNE
$179.87
Share price
-2.33%
Change (1 day)
5.98%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
BeiGene (BGNE) - Total liabilities
Total liabilities on the balance sheet as of June 2023 : $1.93 B
According to BeiGene 's latest financial reports the company's total liabilities are $1.93 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
BeiGene - Total liabilities on balance sheet (from 2014 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2022-12-31 | $1.99 B | -16.94% |
| 2021-12-31 | $2.40 B | 38.78% |
| 2020-12-31 | $1.73 B | 173.14% |
| 2019-12-31 | $0.63 B | 27.8% |
| 2018-12-31 | $0.49 B | 36.93% |
| 2017-12-31 | $0.36 B | -10.74% |
| 2016-12-31 | $0.40 B | 247.55% |
| 2015-12-31 | $0.11 B | 319.22% |
| 2014-12-31 | $27.85 M | -44.87% |
| 2013-12-31 | $50.52 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | $0.62 B | -67.69% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | $11.57 M | -99.40% | 🇺🇸 USA |